Login to Your Account

Selecta Biosciences, 3SBio join forces to develop gout treatment

By Kristine Yang
Contributing Writer

Wednesday, June 18, 2014

HONG KONG – A joint effort by 3SBio Inc. and its new partner Selecta Biosciences Inc. could lead to better treatments for patients with refractory and tophaceous gout. The two companies will work together to combine two products developed independently into one drug that could be distributed globally.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription